Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders. Beckermann, K., Bestvina, C. M., Whisenant, J. G., Borghaei, H., Owonikoko, T., Berry, L. D., Shyr, Y., Liang, C., Selvaggi, G., Wakelee, H. A., Horn, L. LIPPINCOTT WILLIAMS & WILKINS. 2020

View details for Web of Science ID 000560368307512